EYP002 is a new first-in-class chemical series under lead optimization. Initially developed using inhibition of influenza replication as a phenotypic assay, molecules modulate a small family of proteins known to regulate mitochondrial metabolism and stress responses. The scope for therapeutic application extends largely beyond infectious diseases with several other indications having already been positively tested through in vitro and in vivo animal pharmacology studies (e.g. Metabolic Diseases, Oncology, and even a genetic rare disease). ENYO Pharma believes the different target family selectivities within the chemical series will be developable in different therapeutic areas and is open to discussions with potential partners to co-develop different sub-series in a risk-sharing relationship.